Myelodysplastic syndrome with excess blasts

This study tests whether bone marrow from deceased donors can be used to treat people with blood cancers like leukemia and lymphoma. Participants receive a transplant of cryopreserved marrow from a deceased donor or standard cells from a living donor. The goal is to see if the de…

This study compares two ways of giving donor immune cells (DLI) after a stem cell transplant to prevent cancer from coming back in people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. One approach gives the cells early as a preventive measure…

This phase 2 trial tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will enroll 27 adults aged 18 to 75. The main goal is…

Researchers are studying blood samples from 150 adults with lower-risk myelodysplastic syndromes (MDS) who receive luspatercept, a drug that boosts red blood cell production. The goal is to find metabolites and other biomarkers linked to fatigue, a common side effect of the treat…

This study is a registry that will collect medical information and blood samples from 500 adults with myelodysplastic syndromes (MDS) and related conditions. The goal is to learn more about how these diseases develop and progress over time. Participants will not receive any exper…

This study compares survival and other outcomes in patients with acute leukemia or myelodysplastic syndrome who received a stem cell transplant with a personalized dose of an immune-suppressing drug (r-ATG) to similar patients from a large registry who received standard treatment…

This study is testing a new blood test called AlloHeme that looks for tiny traces of a patient's own cells after a stem cell transplant. The goal is to see if the test can predict whether leukemia or MDS will come back before it happens. About 400 adults who have had or will have…

This study follows up to 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track side effects, overall survival, and how long any response lasts. The goal …